Less than one in 10 patients that would benefit from weight-loss injections like Wegovy can access them, states the global health agency as it releases its first recommendations on the therapies.
Given more than one billion people worldwide now living with obesity, it is advocating for more widespread and fairer availability to these injectable treatments.
Based on projections, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"Our new guidelines affirms that excess weight is a chronic disease that can be treated with holistic and lifelong treatment," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are significant hurdles to universal availability to the jabs that can aid individuals in losing considerable weight, explains the body.
Weight-Loss Drug Scarcity
Despite the present most favorable scenario, the manufacturing of these medications could only cover around 100 million people – fewer than 10% of the global need, as stated by the health organization.
The recommendation calls on governments and firms to widen access, through approaches such as voluntary licensing.
A patent on the active ingredient – the main ingredient of the drug Wegovy – is scheduled to end in a number of countries in 2026.
How Obesity Injections Function
These medications replicate a biological compound to slow digestion, reduce hunger and increase feelings of fullness so individuals reduce food intake.
Individuals typically see weight reduction after several weeks of starting on the weekly injections.
Evidence points to users may put most of the weight back on within a year of stopping the treatment, because their usual appetite resume.
To be overweight or obese elevates your chance for developing diseases, including diabetes, heart disease, brain attack, and certain cancers.
Obesity impacts individuals in every country and was associated with over three and a half million deaths worldwide in 2024, according to the health agency.
